We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Vafseo
Published
Product name
Vafseo
Active ingredient
Vadadustat
Submission type
New Chemical Entity
Decision
Approved
Decision date
Registration date
What this medicine was approved for
Vafseo (vadadustat) was approved for the following therapeutic use:
Vafseo is indicated for the treatment of anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
How this medicine works
Vadadustat is an inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH), a group of enzymes that degrade a subunit of hypoxia-inducible factor (HIF) in the presence of oxygen under normal physiological conditions. HIF mediates tissue adaption to low oxygen environments through transcriptional regulation of gene expression. Decreased HIF-PH activity with vadadustat leads to increased cellular levels of HIF thereby stimulating endogenous 13 erythropoietin production, increasing iron mobilization and red blood cell production, resulting in a gradual rate of rise in haemoglobin.
Sponsor